Regarding authentic NPC cell lines:
- Prof SW Tsao 請來 “Georgetown method” 原作，Dr. Liu, Xuefeng，Dr. Liu further introduced two papers, one from the Singapore group (non-malignant NP cells are easier to be established by this method), the other one from Prof Tsao’s lab (北非C15鼻咽癌細胞株之建立)
- 而Prof Tsao自己實驗室新建立的鼻咽癌細胞株則將於Nat Commun發表, stay tuned
- 香港AoE launches a very nice portal site for researchers in NPC field (NPC AoE Research Tissue Bank)
Regarding multiplex immunohistochemistry (multiplex IHC)”
- Rigiv Khanna’s showed beautiful multiple IHC results in his talk, however, no published papers can be found under his group yet.
- Found 4 papers citing “2018/Jan J Immuno 8-color IHC for simultaneous detection…”
- [Review] Antitumor Immunity Is Controlled by Tetraspanin Proteins
- “Tetraspanins and Antigen Presentation” this is so interesting! and maybe relevant to OC3 vs TW2.6
- [Review] Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
- Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
- Chang-Gung memorial hospital is purchasing image system?
Regarding Weissman IL‘s regenerative medicine
- 2017 Nature paper (PD-L1 is another “don’t eat me signal, pdf 5259) : PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
- Here we show that both mouse and human TAMs express PD-1.
- TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers.
- TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion.
- This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
- Figure 1 | Mouse and human TAMs express high levels of PD-1
- Figure 2 | PD-1+ TAM characterization
- Figure 3 | PD-1–PD-L1 blockade promotes anti-tumour efficacy by TAMs.
- Extended Data Figure 4 | Immunocompromised mice also
- exhibit tumour-specific expression of PD-1 on macrophages.
These cells should continually agonize mouse TAM PD-1 signalling24, an effect that should be blocked by administration of the anti-mouse PD-1 antibody, or the anti-human PD-L1 small protein, HAC.
As expected, NSG mice engrafted with DLD-tg(PD-L1)-GFP-luc+ tumours showed tumour-specific expression of PD-1 on TAMs (Extended Data Fig. 4c), and shared the previously observed correlation between PD-1 expression and tumour volume (Extended Data Fig. 4d). Mice treated with either PD-1 blockade (anti-mouse PD-1 antibody) or PD-L1 blockade (HAC) had an equivalent and significant reduction in tumour growth (Fig. 3e).
TAM depletion (See Methods for TAM depletion protocol, and Extended Data Fig. 6a, b for TAM depletion) abrogated the effects that HAC and anti-PD-1 treatment had on tumour size (Fig. 3f). With